secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001104659-25-067579
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharmaceuticals prices $52.5M public offering of common shares and warrants
--------------------------------------------------------------------------------

- Priced $52.5M offering of 31.5M common shares + Series A and B warrants at $1.50/unit; 3.5M pre-funded warrants at $1.499/unit.
- Net proceeds expected ~$48.7M after underwriting commissions and expenses.
- Series A warrants exercisable at $1.50 for 1 year; Series B at $1.875 for 5 years, with mandatory exercise trigger at $3.50 VWAP.
- Proceeds to fund etripamil clinical development and commercial launch for paroxysmal supraventricular tachycardia (PSVT).
- Offering led by TD Cowen, Piper Sandler, Wells Fargo; expected to close July 14, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925067579/0001104659-25-067579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925067579/tm2520713d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-067579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer